[11C]NOP-1A and Cocaine Use Disorders
Overview
The goal of this study is to compared [C-11]NOP-1A binding in recently abstinent cocaine use disorders and controls.
Full Title of Study: “Linking Nociceptive Opioid Peptide (NOP) Receptors With Relapse in Cocaine Use Disorders”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Basic Science
- Masking: None (Open Label)
- Study Primary Completion Date: February 20, 2019
Detailed Description
This will allow for understanding brain stress and anti-stress mechanisms that underlie abuse of cocaine in humans.
Interventions
- Radiation: [C-11]
- Radiolabel
- Drug: NOP-1A
- Tracer
Arms, Groups and Cohorts
- Experimental: Cocaine use disorders
- PET scan
- Experimental: Controls
- PET scan
Clinical Trial Outcome Measures
Primary Measures
- [C-11]NOP-1A VT
- Time Frame: Baseline
- VT-volume of distribution expressed relative to total plasma
Participating in This Clinical Trial
[A]Cocaine use disorders Inclusion criteria:
1. Males or Females 18-50 2. Fulfill DSM-5 Diagnosis for Cocaine use disorder 3. Medically Healthy Major exclusion criteria:
1. Pregnancy or lactation 2. Comorbid medical, psychiatric, drug use disorders (other than cocaine, tobacco use, and recreational marijuana/alcohol use) 3. Metal implants or paramagnetic objects contained within the body which may interfere with the MRI scan 4. Currently employed as radiation worker; or participation in radioactive drug research protocols within the previous year 5. Currently on any psychotropic medications that can influence nociceptin transmission in the brain (e.g., morphine, suboxone, SSRIs, etc.) [B] Healthy controls Inclusion criteria:
1. Males or Females 18-50 2. Absence of present or past psychiatric conditions (including alcohol or drug use disorders) 3. A negative urine drug screen 4. Medically Healthy Major exclusion criteria 1. Pregnancy or lactation 2. Medical, psychiatric or drug & alcohol use disorders 3. Metal implants or paramagnetic objects contained within the body which may interfere with the MRI scan 4. Currently employed as radiation worker; or participation in radioactive drug research protocols within the previous year 5. Currently on any psychotropic medications that can influence nociceptin transmission in the brain 6. Family history of a psychotic disorder, manic episode, drug use disorders in first-degree relatives.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 50 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- University of Pittsburgh
- Collaborator
- National Institute on Drug Abuse (NIDA)
- Provider of Information About this Clinical Study
- Principal Investigator: Rajesh Narendran, Visiting Professor in Radiology – University of Pittsburgh
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.